We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor
News

Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor

Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor
News

Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Dr. Dennis Schmatz Joins SCYNEXIS as Strategic Advisor"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

SCYNEXIS, Inc. has announced that Dr. Dennis Schmatz has joined the company as a strategic advisor. Dr. Schmatz, an industry leader in the field of anti-infectives, will provide counsel to SCYNEXIS' management team as the Company advances its drug development programs.

"Dr. Schmatz brings outstanding capabilities and an extensive background, especially in the area of anti-infectives, and has played a key role in the discovery and development of a number of currently marketed therapeutic agents," said Dr. Yves Ribeill, SCYNEXIS President and Chief Executive Officer.

Ribeill continued, "His contributions to SCYNEXIS will be important as we aggressively pursue the development of our cyclophilin inhibitor technology platform and the discovery of global health therapeutics for neglected diseases."

Dr. Schmatz most recently was the Interim President and Chief Executive Officer of Medicines for Malaria Venture, a nonprofit foundation in Geneva, Switzerland created to discover, develop and deliver new, affordable anti-malarial drugs through effective public-private partnerships. Previously he was the vice president of Merck Research Laboratories USA and the Head of the Tsukuba Research Institute of Banyu Research Laboratories in Japan.

"It's an exciting time to be joining the SCYNEXIS team as both their HCV compounds, SCY-635, and their partnered broad-spectrum antifungal compound, MK-3118, advance through clinical development," Schmatz said. "I see a promising future for SCYNEXIS and am honored to be a part of it."

Advertisement